Studies | EBMT

Top

Study type

Disease

Group

Type of transplant / Cell therapy

Text

Language

Role of HLA Evolutionary Divergence in Mismatched Unrelated Donor Hematopoietic Cell Transplantation for Malignant Hematological Disorders

Retrospective Studies

Acute Lymphatic Leukaemia (ALL)

Acute Myeloid Leukaemia (AML)

Myelodysplastic (MDS) or MDS/MPN

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type de traitement

Investigateur principal

Simona Pagliuca

Association between HLA evolutionary divergence and leukemia relapse after allogeneic SCT from 10/10 HLA matched related/unrelated donor

Retrospective Studies

Acute Myeloid Leukaemia (AML)

Acute Lymphatic Leukaemia (ALL)

Myelodysplastic (MDS) or MDS/MPN

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type de traitement

Investigateur principal

Pietro Crivello, Pietro Merli

Outcome of patients with Intermediate risk Acute Myelogenous Leukemia in first remission and no detectable residual disease (MRD negative) transplanted with a haploidentical donor versus autografted

Retrospective Studies

Acute Myeloid Leukaemia (AML)

Acute Leukemia Working Party (ALWP)

Type de traitement

Investigateur principal

Norbert-Claude GORIN

Comparison of outcomes after unrelated double-unit cord blood and haploidentical peripheral blood stem cell transplantation in adults with acute myeloid leukemia, a study on behalf of Eurocord and ALWP-EBMT

Retrospective Studies

Acute Myeloid Leukaemia (AML)

Acute Leukemia Working Party (ALWP)

Type de traitement

Allogeneic - Haploidentical

Investigateur principal

Annalisa Ruggeri

The role of measurable residual disease (MRD) at the time of allogeneic stem cell transplantation in patients with AML in CR transplanted from unrelated donors with Post transplant cyclophosphamide

Retrospective Studies

Acute Myeloid Leukaemia (AML)

Acute Leukemia Working Party (ALWP)

Type de traitement

Investigateur principal

PTCY MMUD vs Haplo in active disease for AML

Retrospective Studies

Acute Myeloid Leukaemia (AML)

Acute Leukemia Working Party (ALWP)

Type de traitement

Allogeneic - Haploidentical

Investigateur principal

Frédéric Baron

Graft Engineering for allogeneic hematopoietic stem cell transplantation (HSCT) and modified donor lymphocyte infusion (DLI)

Closed Survey/Study

Cellular Therapy & Immunobiology Working Party (CTIWP)

Type de traitement

Investigateur principal

Moniek de Witte

Trends in non sibling donor in HSCT CR2

Retrospective Studies

Acute Leukemia Working Party (ALWP)

Type de traitement

Allogeneic - Haploidentical

Investigateur principal

Trends in donor characteristics for unrelated Stem Cell Transplantation in patients with acute myeloid leukemia

Retrospective Studies

Acute Myeloid Leukaemia (AML)

Acute Leukemia Working Party (ALWP)

Type de traitement

Investigateur principal

Haploidentical versus matched sibling donors hematopoietic stem cell transplantation for adult patients with relapsed/refractory acute lymphoblastic leukemia

Retrospective Studies

Acute Lymphatic Leukaemia (ALL)

Acute Leukemia Working Party (ALWP)

Type de traitement

Allogeneic - Haploidentical

Investigateur principal

Trends in allogeneic stem cell transplantation (HSCT) over two decades in patients with secondary acute myelogenous leukemia (sAML) being transplanted from sibling (MSD) or unrelated donors (UD). A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Retrospective Studies

Acute Myeloid Leukaemia (AML)

Acute Leukemia Working Party (ALWP)

Type de traitement

Investigateur principal

Impact of Specific Adverse Cytogenetic Features on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome with Very Poor Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of EBMT

Retrospective Studies

Myelodysplastic (MDS) or MDS/MPN

Chronic Malignancies Working Party (CMWP)

Type de traitement

Investigateur principal